Guest Column | November 16, 2026

What Happens When Acquisition Due Diligence Ignores Clinical Operations?

By Jose M. Silveiras, MD, clinical operations executive

businessman Head In Clouds-GettyImages-502994785

Imagine being a principal investigator (PI) responsible for patients enrolled in a Phase 2 or 3 clinical trial. Overnight, you receive a letter informing you that the investigational drug has been transferred to a new sponsor, and the questions are just beginning.

You might wonder: Will protocol changes, contracts, budgets, supplies, monitoring, and informed consent overwhelm the site? Will enrolled participants experience interruptions?

Having managed clinical operations through multiple acquisitions involving active Phase 2 and 3 studies, I have witnessed firsthand how corporate decisions made far from investigative sites can create significant operational disruption.

In one transition, a site stopped recruiting because it was uncertain how the acquisition would impact payment. Cash flow is important for sites that depend on industry-sponsored trials. As soon as the site obtained clarity about pending invoices and budget questions, all operations and collaboration returned to normal. The disruption followed an acquisition that had been unfolding behind the scenes, without sufficient coordination with the people conducting the study.

The sponsor’s leadership sees an acquisition as an opportunity for growth and return on investment, but clinical operations, investigative sites, and participants often experience uncertainty, delay, additional work, and avoidable risk. When due diligence fails to consider the operational realities of an ongoing clinical trial, it undermines site trust, slows recruitment, and challenges site operations.

The Missing Voice In Due Diligence

Biopharmaceutical acquisitions involve extensive financial, legal, intellectual property, regulatory, and commercial assessments. Executives evaluate assets, market opportunities, development milestones, competitive positioning, and anticipated returns. These are essential considerations. But a critical question often receives insufficient attention: Can the clinical trial continue safely, compliantly, and efficiently under the proposed new ownership and operating model?

The answer requires direct input from the professionals managing the trial at the sponsor, the CRO (if there is one), and the sites. That’s because clinical operations and site management teams understand practical realities that leadership may overlook:

  • Which investigative sites are actively recruiting, and which are struggling
  • Which PIs have concerns about study continuity
  • Which contracts, budgets, and regulatory documents may require modification
  • How country-specific requirements and ethics committee approvals affect transition timelines
  • Which CRO and vendor relationships are essential to uninterrupted study execution
  • How changes may affect enrolled participants, investigational product availability, and scheduled assessments

These are operational dependencies that can determine whether an acquired clinical asset continues to advance or becomes trapped in costly delays. If leadership excludes clinical operations from due diligence, it may be buying a clinical asset without fully understanding what it will cost to keep that asset moving.

Investigative Sites Cannot Simply Flip A Switch

At the investigative site, a change in ownership can trigger a complex series of regulatory, contractual, financial, and operational activities. Depending on jurisdiction, transaction structure, and nature of the change, these may require the sponsor to update regulatory submissions, sponsor information, trial documentation, contracts, and informed consent materials. Institutional review boards or independent ethics committees may need to review those changes, and regulators may require notifications, approvals, or other actions. Some requirements can be completed relatively quickly. Others depend on external review cycles and simply cannot be accelerated because leadership has established an aggressive integration deadline.

The challenges also differ by site type. Academic medical centers may require extensive legal, financial, and institutional review. Site management organizations may have standardized processes and their own contractual requirements. Independent research sites may need to evaluate the new sponsor’s financial stability and operational capabilities. Some sites may seek to renegotiate budgets or contract terms, particularly when new responsibilities, systems, or administrative requirements are introduced. Plus, some PIs may reasonably ask whether the new sponsor has sufficient funding and commitment to complete the study.

These are legitimate concerns. Investigative sites are not passive extensions of a sponsor’s corporate organization but independent partners with regulatory obligations, financial responsibilities, and duties to their patients. When these realities are ignored, the transition can grow by weeks or months due to operational uncertainty.

Changing CROs Mid-Trial: A Second Layer Of Risk

An acquisition can become even more complicated when the new sponsor replaces the existing CRO. The acquiring company may have an established relationship with another CRO, negotiated pricing, preferred technology platforms, or a desire to consolidate vendor relationships. But a transition during an active clinical trial can affect nearly every element of study execution — from clinical research associates (CRAs) to data management systems to supply logistics.

The outgoing CRO must transfer critical information, documentation, operational knowledge, and outstanding action items to the incoming provider, and the transition itself introduces another important variable: cooperation between the outgoing and incoming organizations.

When a CRO learns that its services are being terminated, the quality and speed of the handover can depend on contractual provisions, transition planning, available resources, and the working relationships between the parties. A poorly managed handover can create gaps in institutional knowledge, oversight, documentation, and accountability.

Sponsor leadership should consider whether the financial and strategic benefits of changing CROs outweigh the operational risks and total transition costs of making that change during an active study.

What Is A Day Of Delay Worth?

Every clinical development executive understands that delays have financial consequences. Yet the cost of disruption is not always fully reflected in acquisition valuations or vendor consolidation projections.

Research by Smith, DiMasi, and Getz1, published in Therapeutic Innovation & Regulatory Science in 2024, estimated average direct costs associated with a day of delay in drug development:

  • $23,737 per day for Phase 2
  • $55,716 per day for Phase 3

These estimates illustrate the financial exposure associated with development delays. Actual financial consequences vary substantially by therapeutic area, protocol, study design, development stage, and nature of the delay, but a hypothetical Phase 3 program experiencing 30 days of delay would mean $1.67 million in estimated delay costs. Additional transition costs could include:

  • Contract renegotiations and legal reviews
  • Regulatory submissions and ethics committee activities
  • CRO transition management and duplicate service costs
  • Site staff retraining and technology implementation
  • Additional clinical operations oversight and vendor coordination
  • Delayed recruitment, monitoring, data cleaning, or database milestones
  • Management time diverted from other corporate priorities

For sponsor leadership, the implication is clear: The purchase price is not the full cost of acquiring a clinical-stage asset. Operational integration must be part of the equation.

The Most Important Stakeholder Is Missing From The Financial Model

There is another cost that cannot be adequately represented in a spreadsheet: the human cost. Clinical trial participants are people who have made an extraordinary commitment. Some are managing serious medical conditions, some have exhausted all available treatments, and others want to help advance future treatments.

They invest their time, accept inconvenience and uncertainty, attend repeated study visits, undergo testing, and place their trust in the PI and research team. For some, participation represents access to an investigational treatment they hope may help them, even though benefit is uncertain.

When an acquisition or CRO change disrupts a study, participants may face new consent requirements, revised schedules, additional communication, or uncertainty about continued participation. In more serious circumstances, interruptions require carefully managed clinical and regulatory responses.

The PI and site team are the people who must explain changes, answer difficult questions, preserve confidence, and maintain oversight. They are also the people whose trust and cooperation the sponsor will need for the success of the trial.

Five Questions Everyone Should Ask

Clinical operations should not be brought into an acquisition or vendor transition only after the strategic decision has been made. Its expertise belongs in the due diligence and transition planning process, with appropriate confidentiality protections.

Before approving a transaction or major CRO change affecting an ongoing clinical trial, leadership should ask five questions:

  1. What is the operational readiness of the asset we’re acquiring?
  2. What changes are necessary, and which are discretionary?
  3. What is the impact on timelines and total acquisition costs?
  4. How will sites and participants be protected from disruption?
  5. Who is accountable for transition readiness and continuity of care?

Make Clinical Operations Part Of The Investment Decision

My recommendation to acquiring companies is straightforward: Include clinical operations and site management experts in due diligence before the transaction closes.

Will their involvement eliminate every risk? Of course not.

Clinical research involves independent investigators, institutions, ethics committees, regulatory authorities, vendors, and participants. No company controls every decision or timeline. But experienced clinical operations professionals know how to anticipate dependencies, recognize warning signs, and build practical mitigation plans. Most importantly, they understand that successful study execution depends on relationships as much as contracts, systems, and schedules. A successful acquisition should preserve the value of the clinical program, not compromise that value through preventable disruption.

Reference:

  1. Smith ZP, DiMasi JA, Getz KA. “New Estimates on the Cost of a Delay Day in Drug Development,” Therapeutic Innovation & Regulatory Science, 2024;58(5):855–862. https://doi.org/10.1007/s43441-024-00667-w

About The Author:

Jose M. Silveiras, MD, is a clinical development leader with more than 20 years of experience in global clinical research. Most recently, he served as global head of site engagement and clinical monitoring at Zenas BioPharma, where he led a team spanning the Americas, Europe, and Asia-Pacific and oversaw site strategy for global Phase 3 programs in partnership with a major CRO. His career includes roles at Ultragenyx, Voyager, and Optum, as well as research at the U.S. Naval Medical Research Center and the National Institute of Allergy and Infectious Diseases (NIAID). He writes and speaks on building site engagement as a measurable function within clinical operations.